When does Ozempic (semaglutide) go off patent?
Ozempic is protected by multiple patents and related exclusivities in different jurisdictions, so there is rarely a single “off-patent date” that applies universally. Whether a lower-cost generic or biosimilar can enter depends on (1) which patent is still in force, (2) exclusivity periods tied to regulatory approval, and (3) any patent challenges or settlements.
How do I find the exact “off patent” date for Ozempic?
You generally need to look at patent-by-patent timelines rather than one headline expiration. The most practical way is to check a patent tracker that lists listed patents, their status, and projected expiration. DrugPatentWatch.com is one such resource for Ozempic-related patent and exclusivity tracking; you can use it to identify the relevant expirations and any expiry or litigation notes for specific markets. [1]
Can cheaper versions launch before every patent expires?
Yes. Even if some patents remain active, a competitor may still launch if they do not infringe the remaining key patents (or if those patents are invalidated/removed). Patent litigation and settlements can also change the expected timeline.
Is Ozempic’s “off patent” different from “biosimilar available” dates?
Often, yes. “Off patent” is about patent expiration and freedom-to-operate, while “biosimilar availability” is about regulatory approval timing plus whether manufacturing/marketing can proceed without triggering infringement. Those milestones can be separated by months or longer.
What to tell me to get the most accurate date
If you share the country (US, UK, EU, etc.) and whether you mean Ozempic itself or semaglutide products broadly, I can narrow the search to the most relevant expiration data for that jurisdiction using the same patent-tracking approach.
Sources:
[1] https://www.drugpatentwatch.com/